Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder

Stahl, Stephen M., Sommer, Bernd, Allers, Kelly A.·2011·The Journal of Sexual Medicine

Abstract

Introduction: Flibanserin is a novel pharmacologic agent in late-stage clinical testing for hypoactive sexual desire disorder (HSDD) in premenopausal women. Aim: The aim of this article is to review the hypothetical mechanism of action of flibanserin in HSDD. Methods: A literature review was conducted of all published works on flibanserin and on related studies of serotonin (5-HT)1A receptors and 5-HT2A receptors, including their actions on monoamines and on sexual function. Main Outcome Measures: The main outcome measures are preclinical pharmacologic actions, especially changes in regional monoamines following treatment with flibanserin. Results: At clinically relevant doses, flibanserin acts predominantly at 5-HT1A receptors as an agonist and secondarily at 5-HT2A receptors as an antagonist. Additional binding actions within an order of magnitude of its 5-HT1A affinity, which are not likely to be clinically relevant, include weaker antagonist actions at 5-HT2C and 5-HT2B receptors, and less defined activity at dopamine (DA) D4 receptors. The 5-HT1A actions of flibanserin are only seen postsynaptically, which is unlike other agents such as buspirone that act at presynaptic 5-HT1A receptors. Furthermore, the postsynaptic actions of chronic flibanserin administration appear to demonstrate a preference for some populations of postsynaptic 5-HT receptors, particularly those that are located on the prefrontal cortex (PFC) pyramidal neurons, which regulate monoamine release in certain selective brain regions. Conclusions: The regional selectivity of flibanserin results in a unique pattern of monoamine modulation. Sustained increases in baseline of DA and norepinephrine (NE) are observed in the PFC, and flibanserin dosing increases DA and NE levels above the basal changes. Conversely, flibanserin induces transient decreases in 5-HT levels in some brain areas such as the PFC, nucleus accumbens, and hypothalamus, but not in other brain areas such as the hippocampus. Therefore, since DA and NE are excitatory and 5-HT is inhibitory to sexual desire and arousal, it is tempting to postulate that the actions of flibanserin on serotonin receptors at the PFC pyramidal neurons, resulting in increased DA and NE yet reduced 5-HT in the PFC, are the mechanistic underpinnings of enhancing sexual desire in HSDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.2010.02032.x

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 293

Metadata

Authors
Stahl, S. M., Sommer, B., & Allers, K. A.
Venue
The Journal of Sexual Medicine
Published
2011-01-01
Volume
8
Issue
1
Pages
15-27
ISSN
  • 1743-6095 (ISSN-L)
  • 1743-6109
OpenAlex
W1600990718
Cited by
293
References
59
FWCI
6.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder. https://app.cochat.ai/papers/10.1111/j.1743-6109.2010.02032.x
The paper
Stahl, S. M., Sommer, B., & Allers, K. A. (2011). Multifunctional Pharmacology of Flibanserin: Possible Mechanism of Therapeutic Action in Hypoactive Sexual Desire Disorder. The Journal of Sexual Medicine. https://doi.org/10.1111/j.1743-6109.2010.02032.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.